- What is the most critical communication to relay to the receiving facility?
Answer: Declaring a 'STEMI Alert' and providing your estimated time of arrival.
When you encounter a suspected STEMI (ST-Elevation Myocardial Infarction) in the field, your primary goal is activating the cardiac catheterization lab and getting the patient to definitive care as quickly as possible. Time is myocardium – every minute of delay increases heart muscle death.
The correct answer is A because declaring a "STEMI Alert" immediately mobilizes the entire cardiac team at the receiving facility. This pre-arrival notification allows the catheterization lab team to prepare for immediate intervention, potentially saving 30-60 minutes of door-to-balloon time. Your ETA helps them coordinate resources and staff activation. For STEMI patients, this communication can literally be the difference between life and death, or between a good outcome and permanent heart damage.
Option B is problematic because while the closest hospital is nearer, STEMI patients benefit most from primary PCI (percutaneous coronary intervention) at facilities equipped with cardiac catheterization labs. The 15-minute transport difference is often worth it for specialized care.
Option C misses the urgency entirely – pain management is secondary to reperfusion therapy in STEMI protocols.
Option D wastes precious time on non-critical information when immediate action is needed.
Remember for the NREMT: STEMI recognition triggers a time-sensitive protocol chain. Your field communication directly impacts patient outcomes. Always prioritize STEMI alerts over routine reporting when you have clear ST-elevation findings. The cardiac center's specialized capabilities usually outweigh modest transport time differences in these cases.
- Based on this presentation, which of the following is the most appropriate initial action?
Answer: Acquire a 12-lead ECG and treat her symptoms as a potential cardiac emergency.
The patient's age, symptoms (epigastric pain, nausea, diaphoresis), and the statement that it 'feels different' from her GERD are highly suggestive of an atypical presentation of Acute Coronary Syndrome (ACS). The AEMT's priority is to treat for potential cardiac ischemia. Acquiring a 12-lead ECG is a critical step in assessment. Administering oral glucose is inappropriate without a blood glucose reading indicating hypoglycemia. Having the patient self-medicate with an antacid delays definitive care and is based on an unconfirmed assumption. Oxygen is not indicated as her SpO2 is 97%, and routine oxygen administration in normoxic ACS patients is not recommended.
- What is the primary reason for establishing IV access in a potentially unstable cardiac patient?
Answer: To have a reliable route for medication administration if the patient deteriorates.
In the prehospital setting, the main reason for establishing IV access in an ACS patient is to have a patent route for potential emergency medications. If the patient develops a life-threatening dysrhythmia, becomes hemodynamically unstable, or goes into cardiac arrest, IV access is crucial for administering drugs like amiodarone, lidocaine, epinephrine, or atropine. Large fluid boluses are generally not indicated unless there is hypotension, particularly in a right ventricular MI. Drawing blood and therapeutic hypothermia are not the primary prehospital goals of IV placement by an AEMT.
- What is the AEMT's most immediate priority?
Answer: Begin high-quality chest compressions and apply the AED/defibrillator.
When you encounter a patient who suddenly becomes unresponsive, pulseless, and apneic, you're dealing with cardiac arrest - a true emergency where every second counts. The priority is always immediate CPR and defibrillation per current resuscitation guidelines.
Answer A is correct because high-quality chest compressions must begin immediately to maintain circulation, and the AED/defibrillator should be applied as quickly as possible. Given this patient's presentation with chest pain followed by sudden collapse, he's likely in a shockable rhythm like ventricular fibrillation. Early defibrillation dramatically improves survival rates, but only if preceded by effective compressions.
Answer B is wrong because IV fluids won't restore circulation in cardiac arrest - the heart isn't pumping at all. Hypotension isn't the primary problem here; the absence of any cardiac output is.
Answer C is incorrect because airway management, while important, comes after circulation in cardiac arrest. The "CAB" sequence (Compressions, Airway, Breathing) prioritizes chest compressions first. You can provide initial ventilations with a bag-mask while compressions continue.
Answer D is wrong because epinephrine administration requires an established IV/IO and comes later in the algorithm. You can't delay compressions and defibrillation to contact medical control - these interventions fall within your scope and are time-critical.
Remember: In cardiac arrest scenarios on the NREMT, always think "compressions and electricity first." Everything else - medications, advanced airways, fluid therapy - comes after you've addressed the fundamental problem of absent circulation.
- Five minutes after administering the medication, which two assessments are the most important to repeat?
Answer: Pain level and blood pressure.
When you encounter questions about medication administration and follow-up care, always think about the specific effects and potential complications of the drug given. Nitroglycerin is a potent vasodilator that primarily affects two key parameters you must monitor closely.
The correct answer is D because nitroglycerin's primary therapeutic effect is pain relief through coronary vasodilation, and its most significant side effect is hypotension due to systemic vasodilation. After giving sublingual nitroglycerin, you must reassess pain level to determine if the medication is working and check blood pressure to ensure the patient hasn't developed dangerous hypotension. A drop in systolic BP below 90 mmHg or a decrease of 30+ mmHg from baseline can compromise perfusion and contraindicate further nitroglycerin doses.
Choice A is incorrect because while lung sounds and pulse oximetry are important cardiac assessments, they don't directly relate to nitroglycerin's immediate effects and aren't priority reassessments within five minutes of administration.
Choice B is wrong because pupil response and blood glucose are neurological assessments unrelated to nitroglycerin's cardiovascular effects. These wouldn't be expected to change from this medication.
Choice C is incorrect because heart rhythm and respiratory rate, while important vital signs, aren't the primary parameters affected by nitroglycerin. The drug doesn't typically cause immediate rhythm changes or respiratory depression.
Remember this pattern: after giving any medication, always reassess the specific problem you're treating (chest pain) and monitor for the drug's most dangerous side effect (hypotension with nitroglycerin). This approach applies to many AEMT pharmacology questions.
- The presence of bilateral crackles is most indicative of which complication of an MI?
Answer: Left ventricular failure.
An acute MI can damage the heart muscle, impairing its ability to pump. When the left ventricle fails, it cannot effectively pump blood out to the body. This causes blood to back up into the pulmonary circulation, increasing pressure in the pulmonary capillaries and forcing fluid into the alveoli. This fluid is what creates the sound of crackles (rales) on auscultation and is a hallmark sign of left-sided heart failure and pulmonary edema. Right ventricular failure typically presents with peripheral edema and JVD, not pulmonary crackles.
- Which sequence represents the most appropriate initial set of interventions for this patient?
Answer: Administer aspirin, acquire 12-lead ECG, administer nitroglycerin, then establish IV access.
When managing suspected acute coronary syndrome (ACS), your interventions must follow a logical sequence that prioritizes both diagnostic information and life-saving treatments while considering practical limitations.
The correct sequence starts with aspirin administration because it's the most critical early intervention for ACS. Aspirin blocks platelet aggregation and can prevent clot expansion, making it a time-sensitive treatment that should never be delayed. Next, you acquire the 12-lead ECG to identify STEMI versus NSTEMI, which guides your treatment pathway. Nitroglycerin follows because you need the ECG first to rule out right-sided MI or inferior STEMI with RV involvement, where nitroglycerin could cause dangerous hypotension. IV access comes last since it's procedural and doesn't directly treat the cardiac event.
Option A delays aspirin unnecessarily while prioritizing IV access, which wastes precious time. Option B gives nitroglycerin before obtaining the ECG, which could cause hemodynamic compromise if the patient has a right-sided MI. Option C also gives nitroglycerin before ensuring it's safe via ECG interpretation, and it delays the most important medication (aspirin).
Remember the ACS priority hierarchy: aspirin first (anti-platelet therapy is crucial), ECG second (guides treatment decisions), then symptom relief with nitroglycerin if safe, and finally supportive measures like IV access. Time is myocardium, so don't delay definitive treatments for procedural tasks that can wait.
- Which of the following interventions regarding oxygen therapy is most appropriate for this patient?
Answer: Withhold supplemental oxygen and continue to monitor his SpO2.
Current guidelines recommend administering supplemental oxygen to ACS patients only if they are hypoxic (SpO2 < 94%), in respiratory distress, or show signs of shock. This patient's SpO2 is 98%, indicating he is not hypoxic. Research has shown that hyperoxia can be harmful in ACS by increasing coronary vascular resistance and oxidative stress. Therefore, withholding oxygen is the correct approach. Applying a non-rebreather or nasal cannula is not indicated. A BVM is for patients who are apneic or have inadequate respiratory effort.
- Which finding on the cardiac monitor would be the strongest relative contraindication to administering a second dose of nitroglycerin?
Answer: Sinus bradycardia at a rate of 52.
When evaluating cardiac rhythms before administering nitroglycerin, you need to consider how this vasodilator will affect the patient's cardiovascular status. Nitroglycerin reduces preload and can decrease blood pressure, which may compromise cardiac output in certain rhythm disturbances.
Bradycardia at 52 bpm (option A) represents the strongest relative contraindication because the heart is already beating slowly. When you add nitroglycerin's vasodilating effects, you risk further reducing cardiac output through decreased venous return. The combination of slow heart rate and reduced preload can lead to hypotension and inadequate perfusion, especially since this patient's systolic BP is already modest at 112 mmHg.
Option B (frequent PVCs) doesn't contraindicate nitroglycerin use. While PVCs indicate cardiac irritability, nitroglycerin may actually help by improving coronary perfusion if the underlying issue is ischemia.
Option C (sinus tachycardia at 110) is not a contraindication. The faster heart rate can help maintain cardiac output even if preload decreases from nitroglycerin's effects.
Option D (controlled atrial fibrillation) presents no specific contraindication to nitroglycerin. The key word "controlled" indicates the ventricular response rate is acceptable, so cardiac output should be maintained despite the vasodilation.
Study tip: Remember that bradycardia plus vasodilators equals potential trouble. Always assess both heart rate and blood pressure together when considering nitroglycerin - you need adequate rate AND preload to maintain perfusion.
- This change in his symptom pattern is significant because it suggests a transition from:
Answer: stable angina to unstable angina.
Stable angina has a predictable pattern, is provoked by exertion, and is relieved by rest or nitroglycerin. Unstable angina is characterized by a change in this pattern: it occurs at rest, is new in onset, or is more severe/prolonged than previous episodes. The patient's presentation—chest pain at rest that is unresponsive to his usual dose of nitroglycerin—is the classic definition of unstable angina, which is a form of ACS and indicates a higher risk of MI.
- What is the most appropriate action regarding aspirin administration for this patient?
Answer: Administer an additional 243 mg of aspirin for a total of 324 mg.
The recommended dose of aspirin for suspected ACS is 162 to 324 mg. The patient has already taken 81 mg. To reach the full therapeutic dose of 324 mg, the AEMT should administer an additional 243 mg (three 81 mg tablets). Administering only one more tablet (total of 162 mg) is within the acceptable range, but providing the full 324 mg is also a standard and appropriate protocol. Withholding aspirin would fail to provide the full antiplatelet benefit. Requesting a different agent is outside the AEMT scope and unnecessary.
- Given the clinical and ECG findings, which intervention is contraindicated?
Answer: Administration of 0.4 mg sublingual nitroglycerin.
The patient's presentation is consistent with an inferior wall MI (STEMI in leads II, III, aVF), which can involve the right ventricle. Right ventricular involvement often makes the patient preload-dependent. Nitroglycerin causes vasodilation, which reduces preload and can lead to severe hypotension in these patients. The patient's borderline hypotension (systolic BP 94 mmHg) is an additional strong contraindication. Aspirin and rapid transport are indicated. A fluid bolus may be appropriate to support blood pressure in a suspected right ventricular MI.
- Given this patient's presentation and history, the AEMT should have a high index of suspicion for:
Answer: an acute coronary syndrome equivalent.
Elderly patients and those with diabetes mellitus often present with atypical or 'silent' symptoms of ACS. Classic chest pain may be absent. Instead, they may present with symptoms like generalized weakness, dyspnea, fatigue, syncope, or epigastric discomfort. These are known as ACS equivalents. Given the patient's risk factors (age, diabetes) and symptoms (weakness, dyspnea, pale/moist skin, tachycardia), the AEMT must maintain a high index of suspicion for a cardiac event, even without chest pain.
- These findings are most suggestive of a condition that differs from typical ACS because the pain is:
Answer: pleuritic and positional in nature.
The key differentiating feature described is that the pain is pleuritic (worsens with inspiration) and positional (worsens when lying flat, improves when leaning forward). This pattern is classic for pericarditis, not typical myocardial ischemia. While ACS can present as sharp pain and is often on the left side, the positional and pleuritic nature is the strongest indicator of a non-ACS etiology. It is crucial for the AEMT to recognize these differentiating features during assessment.
- While treatment for this patient generally follows standard ACS protocols, the AEMT should recognize that the underlying cause is likely:
Answer: profound and sustained coronary artery vasospasm.
Cocaine is a powerful sympathomimetic that causes intense vasoconstriction. In the coronary arteries, this can lead to a vasospasm severe enough to completely occlude the vessel, causing a transmural infarction (STEMI) even in the absence of significant underlying atherosclerotic disease. Recognizing this etiology is important for the healthcare team, as management may differ slightly (e.g., preference for benzodiazepines). For the AEMT, the key is to recognize the link between the drug use and the likely mechanism of infarction.
- What is the most critical priority for this patient?
Answer: Initiating immediate transport to the PCI-capable hospital.
For a patient with a STEMI, the primary goal is rapid reperfusion of the occluded coronary artery, which is achieved through percutaneous coronary intervention (PCI). Time is muscle. Delays on scene for procedures that can be performed en route, such as a third IV attempt or a detailed secondary assessment, are detrimental. While IV access is important, it should not delay transport. The most critical action is to get the patient to the catheterization lab as quickly as possible.
- Prior to assisting the patient with his nitroglycerin, which question is most critical to ask?
Answer: Have you taken any phosphodiesterase inhibitors recently?
Phosphodiesterase inhibitors (e.g., sildenafil, tadalafil) are used for erectile dysfunction and pulmonary hypertension. When combined with nitroglycerin, they can cause profound, life-threatening hypotension. This is an absolute contraindication and must be assessed before administering nitroglycerin. While other history questions are relevant to the overall assessment, the use of these specific drugs poses the most immediate risk in this context.
- What is the most appropriate next action?
Answer: Place the patient supine and administer a normal saline fluid bolus.
The patient has developed symptomatic bradycardia and hypotension, likely due to an evolving inferior wall MI or as a side effect of the nitroglycerin. The immediate priority is to treat the hypoperfusion. A third dose of nitroglycerin is strictly contraindicated due to the hypotension. The first step is to manage the hypotension by placing the patient supine and administering a normal saline fluid bolus to increase preload and support blood pressure. While medical control contact may be warranted, the immediate intervention takes priority.
- In managing this patient, what is the primary rationale for acquiring a 12-lead ECG as soon as possible?
Answer: To identify the presence of ST-segment elevation, which requires rapid transport to a specialized facility.
While a 12-lead ECG provides information on rate and rhythm, its most crucial function in the prehospital setting for an ACS patient is to identify ST-segment elevation (STEMI). A STEMI indicates a completely occluded coronary artery and is a time-sensitive emergency requiring immediate reperfusion therapy, typically at a PCI-capable hospital. This finding fundamentally changes the patient's destination and treatment pathway. While an ECG can suggest an MI over unstable angina, its key role is guiding the transport decision.
- This history should prompt the AEMT to be cautious when administering nitroglycerin due to the possibility of what underlying condition?
Answer: Severe aortic stenosis.
When you encounter a patient with chest pain and a history of a "tight" heart valve, you're dealing with a potential cardiac emergency that requires careful medication consideration. The description of a "tight" valve indicates stenosis, where the valve opening is narrowed and restricts blood flow.
Severe aortic stenosis (D) is the critical condition here. The aortic valve controls blood flow from the left ventricle to the body, and when it's severely stenotic, the heart depends on adequate preload (venous return) to maintain cardiac output. Nitroglycerin causes venodilation, reducing preload by pooling blood in the venous system. In severe aortic stenosis, this reduction in preload can cause a dangerous drop in cardiac output and blood pressure, potentially leading to cardiac arrest.
Option A, mitral valve regurgitation, involves backward flow but doesn't create the preload dependency that makes nitroglycerin dangerous. Option B, pulmonic insufficiency, affects the right side of the heart and pulmonary circulation, not systemic blood flow that nitroglycerin primarily influences. Option C, tricuspid valve prolapse, also involves the right heart and wouldn't create the same contraindication to nitroglycerin.
The patient's hypertension (160/90) might seem to indicate nitroglycerin would be helpful, but in severe aortic stenosis, this elevated pressure may be compensatory to maintain adequate perfusion through the narrowed valve.
Remember this pattern: "tight valve" plus chest pain should immediately make you think aortic stenosis and exercise extreme caution with any vasodilator, especially nitroglycerin. When in doubt, consult medical control before administering.
